Clinical trial
A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma
NCT00327249 is registered in ClinicalTrials.gov with AmpliMed Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma
- Lead sponsor
- AmpliMed Corporation
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 31, 2005
- Completion date
- January 31, 2008
- Enrollment
- Not reported
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.